Region Oestergoetland
Verified site
Linkoping, Sweden
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This study focuses on patients with Type 2 Diabetes who have been diagnosed within the last 4 years. The research compares two different medications: dapagliflozin (which belongs to a group of medicines called SGLT2 inhibitors) and metformin. The purpose is to determine whether treatment with dapagliflozin compared to metformin is more beneficial for patients in the early stages of Type 2 Diabetes.
The study examines how these medications affect patients' survival and prevents complications related to diabetes. These complications include problems with the heart and blood vessels, as well as issues affecting small blood vessels that can lead to problems with the eyes, kidneys, and feet. Participants will receive either dapagliflozin or metformin as oral tablets daily for up to 72 months.
Throughout the study, researchers will monitor various health indicators including blood sugar levels, cholesterol, blood pressure, body weight, and kidney function. They will also track any diabetes-related complications and collect information about the participants' overall health and well-being. The information will be gathered through regular check-ups and through the Swedish National Diabetes Register.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
16 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Linkoping, Sweden
Umea, Sweden
Gothenburg, Sweden
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a medication that belongs to a class called SGLT2 inhibitors. It works by helping the kidneys remove excess sugar from the blood through urine. This medication is used to treat type 2 diabetes and can help reduce the risk of heart and kidney complications in diabetic patients.
is a widely used first-line medication for treating type 2 diabetes. It works by reducing the amount of sugar produced by the liver and helping the body respond better to insulin. This medication helps control blood sugar levels and is often prescribed as an initial treatment for newly diagnosed diabetes patients.
An oral medication belonging to the SGLT2 inhibitor class used in the treatment of Type 2 Diabetes. This drug works by preventing glucose reabsorption in the kidneys, leading to increased glucose excretion in urine and reduced blood sugar levels. It's available in tablet form and is typically taken once daily, offering an alternative treatment approach to traditional diabetes medications with the added benefit of potential cardiovascular protection.
A first-line oral medication for Type 2 Diabetes that belongs to the biguanide class of drugs. It works by reducing glucose production in the liver, decreasing glucose absorption in the intestines, and improving insulin sensitivity in body tissues. Typically taken in tablet form once or twice daily with meals, metformin has been widely used for decades and is considered the gold standard in diabetes treatment due to its proven safety profile and effectiveness in blood sugar control.
A chronic metabolic disorder characterized by high blood sugar levels due to the body's ineffective use of insulin or insufficient insulin production. The condition typically develops gradually, with the pancreas initially producing extra insulin to compensate for insulin resistance. Over time, the body becomes less able to process glucose effectively, leading to elevated blood sugar levels. The condition can affect multiple body systems and is often associated with lifestyle factors such as diet and physical activity. Type 2 diabetes typically appears in adults, though it can develop at any age.
A complication affecting the eyes where diabetes damages the blood vessels in the retina. The condition develops gradually as high blood sugar levels cause changes in the retinal blood vessels, which may swell, leak, or close off completely. The affected blood vessels can cause vision changes and may stimulate the growth of new, abnormal blood vessels on the retina's surface.
A kidney condition that develops gradually in some people with diabetes. The disorder affects the kidneys' filtering system, particularly the tiny blood vessels that filter waste from the blood. High blood sugar levels can damage these blood vessels over time, leading to changes in kidney function. The condition develops slowly over several years.
A condition where diabetes affects the feet through nerve damage and poor circulation. The disorder can cause changes in skin condition, reduced sensation in the feet, and alterations in foot structure. These changes develop gradually and can affect how the feet function during daily activities. The condition involves both nerve and blood vessel changes in the feet.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.